1. Home
  2. ERAS vs HLLY Comparison

ERAS vs HLLY Comparison

Compare ERAS & HLLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ERAS
  • HLLY
  • Stock Information
  • Founded
  • ERAS 2018
  • HLLY 1903
  • Country
  • ERAS United States
  • HLLY United States
  • Employees
  • ERAS N/A
  • HLLY N/A
  • Industry
  • ERAS Biotechnology: Pharmaceutical Preparations
  • HLLY Auto Parts:O.E.M.
  • Sector
  • ERAS Health Care
  • HLLY Consumer Discretionary
  • Exchange
  • ERAS Nasdaq
  • HLLY Nasdaq
  • Market Cap
  • ERAS 348.4M
  • HLLY 353.7M
  • IPO Year
  • ERAS 2021
  • HLLY N/A
  • Fundamental
  • Price
  • ERAS $1.37
  • HLLY $2.01
  • Analyst Decision
  • ERAS Strong Buy
  • HLLY Strong Buy
  • Analyst Count
  • ERAS 6
  • HLLY 6
  • Target Price
  • ERAS $4.83
  • HLLY $5.21
  • AVG Volume (30 Days)
  • ERAS 1.7M
  • HLLY 384.5K
  • Earning Date
  • ERAS 08-11-2025
  • HLLY 08-06-2025
  • Dividend Yield
  • ERAS N/A
  • HLLY N/A
  • EPS Growth
  • ERAS N/A
  • HLLY N/A
  • EPS
  • ERAS N/A
  • HLLY N/A
  • Revenue
  • ERAS N/A
  • HLLY $596,632,000.00
  • Revenue This Year
  • ERAS N/A
  • HLLY $0.08
  • Revenue Next Year
  • ERAS N/A
  • HLLY $4.60
  • P/E Ratio
  • ERAS N/A
  • HLLY N/A
  • Revenue Growth
  • ERAS N/A
  • HLLY N/A
  • 52 Week Low
  • ERAS $1.01
  • HLLY $1.60
  • 52 Week High
  • ERAS $3.45
  • HLLY $4.08
  • Technical
  • Relative Strength Index (RSI)
  • ERAS 46.81
  • HLLY 45.79
  • Support Level
  • ERAS $1.31
  • HLLY $2.05
  • Resistance Level
  • ERAS $1.59
  • HLLY $2.13
  • Average True Range (ATR)
  • ERAS 0.13
  • HLLY 0.07
  • MACD
  • ERAS -0.02
  • HLLY 0.00
  • Stochastic Oscillator
  • ERAS 25.00
  • HLLY 45.57

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.

About HLLY Holley Inc.

Holley Inc is a designer, marketer, and manufacturer of high-performance automotive aftermarket products, featuring a portfolio of iconic brands serving the car and truck industry. It offers a diversified line of performance automotive products including fuel injection systems, tuners, exhaust products, carburetors, safety equipment and various other performance automotive products. The Company's products are designed to enhance street, off-road, recreational and competitive vehicle performance through increased horsepower, torque and drivability. The company's brands include Holley, APR, MSD and Flowmaster, among others. It derives revenue from the U.S. and Italy, of which prime revenue is derived from the U.S.

Share on Social Networks: